| PSMB7 — Proteasome Subunit Beta Type-7 | |
|---|---|
| Symbol | PSMB7 |
| Full Name | Proteasome Subunit Beta Type-7 |
| Also Known As | Proteasome subunit Z, MC14 |
| Chromosome | 9q34.3 |
| NCBI Gene | 5719 |
| Ensembl | ENSG00000136930 |
| OMIM | 176843 |
| UniProt | P99416 |
| Protein Class | Protease, Hydrolase |
| Diseases | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), Proteasome Dysfunction |
| Expression | Ubiquitous (all tissues) |
Psmb7 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PSMB7 (Proteasome Subunit Beta Type-7), also known as Proteasome Subunit Z, is a gene encoding one of the three constitutive catalytic subunits of the 20S proteasome core particle. Located on chromosome 9q34.3, PSMB7 mediates the trypsin-like proteolytic activity of the standard (constitutive) proteasome, which is essential for general protein degradation and cellular homeostasis [1][2].
Unlike the immunoproteasome subunits (PSMB8, PSMB9, PSMB10), PSMB7 is constitutively expressed in all cell types and tissues, including neurons, where it plays a fundamental role in maintaining protein homeostasis. The proteasome, often called the "garbage disposal" of the cell, degrades damaged, misfolded, and oxidized proteins, as well as short-lived regulatory proteins involved in cell cycle, transcription, and signal transduction [3].
Dysregulation of PSMB7 function has been strongly implicated in neurodegenerative diseases, where impaired proteasome activity contributes to the accumulation of toxic protein aggregates characteristic of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis [4][5].
PSMB7 encodes the beta2 subunit of the 20S proteasome. The proteasome assembly process involves:
PSMB7 is one of three constitutive catalytic subunits:
PSMB7 mediates trypsin-like proteolytic activity:
The proteolytic activity of PSMB7 can be modulated by:
PSMB7 functions at the core of the ubiquitin-proteasome system (UPS):
This pathway is essential for:
In Alzheimer's disease (AD), PSMB7 dysfunction contributes to:
Studies have shown:
In Parkinson's disease (PD), PSMB7 plays a critical role in:
Key findings:
In ALS, PSMB7 dysfunction contributes to:
Research demonstrates:
PSMB7 is also implicated in Huntington's disease:
PSMB7 is ubiquitously expressed at high levels:
In the brain:
PSMB7 is a potential therapeutic target:
Proteasome activators: Compounds that enhance PSMB7 activity may help clear toxic aggregates [10].
Gene therapy: Viral vector delivery of PSMB7 to enhance proteasome function.
Combination approaches: Targeting both proteasome and autophagy (dual therapy).
Small molecule modulators: Developing specific PSMB7 activators for neurodegeneration.
The study of Psmb7 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.